Bladder Calcification in a Male: Evaluation and Management
Bladder calcification in a male requires urgent cystoscopy with biopsy to exclude bladder malignancy, as this is the only definitive way to rule out cancer and establish the underlying etiology 1.
Immediate Diagnostic Approach
The evaluation must proceed systematically to identify the cause, as bladder wall calcification has a limited differential diagnosis with serious implications:
Initial Imaging Assessment
- CT scan (non-contrast-enhanced) is the standard imaging modality to characterize the calcification pattern, location, and extent 2
- Review multiplanar reformatted images carefully—calcifications may mimic bladder stones but represent other pathologies like urachal remnants or mural calcification 3
- Plain radiography (KUB) can help differentiate calcification patterns but has limited sensitivity 2
- Ultrasound has only 45% sensitivity and should not be relied upon as the sole imaging modality 2
Critical History Elements
Obtain specific details about:
- Prior bladder cancer and intravesical therapy (BCG or mitomycin C) 4, 5, 6
- Geographic exposure to schistosomiasis (most common cause historically) 1
- Recent severe COVID-19 infection (emerging cause of diffuse bladder calcification) 7
- Cyclophosphamide use or tuberculosis exposure 1
- Lower urinary tract symptoms and their timeline
Mandatory Cystoscopy with Biopsy
Cystoscopy with biopsy of involved tissues is almost always necessary for confirmation and to rule out bladder neoplasia 1. This is non-negotiable because:
- Primary bladder carcinoma accounts for approximately 30% of bladder calcification cases 1
- Calcified bladder carcinoma occurs in only 0.5% of bladder cancers but carries significant mortality risk 8
- Dystrophic calcification from prior intravesical therapy can coexist with recurrent transitional cell carcinoma 4
Differential Diagnosis by Frequency
Based on the largest case series 1:
- Schistosomiasis (42% of cases) - thin arcuate mural pattern
- Primary bladder carcinoma (32% of cases) - irregular, often central calcification
- Encrustation cystitis (11% of cases)
- Intravesical therapy complications (BCG, mitomycin C) - diffuse dystrophic calcification 5, 6
- Rare causes: tuberculosis, amyloidosis, cyclophosphamide-induced cystitis, COVID-19 sequelae
Laboratory Workup
Obtain:
- Urine culture to identify urea-splitting organisms (encrustation cystitis)
- Urine cytology if malignancy suspected 9
- Creatinine and electrolytes 2
- Consider tuberculosis testing if endemic area or risk factors present
Management Algorithm
If Biopsy Shows Malignancy:
- Manage according to NCCN bladder cancer guidelines with staging, consideration for radical cystectomy, and systemic therapy based on extent 9
- Pure central calcification in bladder masses usually indicates malignancy 10
If Biopsy Shows Benign Dystrophic Calcification:
- Transurethral resection of calcified deposits if symptomatic 4
- Serial cystoscopy follow-up (3-month intervals initially) to monitor for recurrence 4
- Stone analysis typically shows calcium phosphate predominance 7
If Infectious Etiology Identified:
- Treat underlying infection appropriately
- Consider repeat imaging after treatment completion
Critical Pitfalls to Avoid
- Never assume calcification is benign without tissue diagnosis—bladder cancer can present with calcification 8
- Don't mistake calcified urachal remnants or phleboliths for bladder pathology; use multiplanar CT reformats 3
- Don't delay cystoscopy in patients with prior intravesical therapy—calcification can coexist with recurrent cancer 4
- Recognize that even a single dose of intravesical mitomycin C can cause extensive calcification within weeks 6
Special Considerations
For patients with prior intravesical BCG or mitomycin C therapy, dystrophic calcification is a known complication 5, 6. However, this diagnosis of exclusion requires:
- Negative malignancy on biopsy
- Temporal relationship to therapy
- Ongoing surveillance for recurrent disease
The cornerstone of management remains tissue diagnosis through cystoscopy with biopsy to exclude the 30% risk of underlying malignancy 1.